Titan VCT portfolio company story: Quit Genius
A digital clinic partnering with employers, health plans, pharmacy benefit managers and individuals to help conquer substance addiction.
What Quit Genius does
Quit Genius partners with employers, health plans, pharmacy benefit managers and individuals to help conquer substance addictions through behavioural therapy treatments and approved medications. Addiction is estimated to impact nearly 21 million Americans, according to statistics from the Addiction Center ¹, and it is a similar story throughout the world. That is why co-founders Yusuf Sherwani (CEO), Ma roof Ahmed (COO) and Sarim Siddiqui (CPO) developed Quit Genius.
Why we like it
Now operating in the UK and 50% of States in America, its programmes can be accessed by more than two million people, and research has shown a five times greater likelihood of users quitting over the course of a year compared to other programs. It’s the world’s first digital clinic created by a diverse team of doctors, technologists and designers delivering comprehensive Medication-Assisted Treatment (MAT) for multiple addictions, 100% virtually, with coaches providing emotional support and education. We’re enormously excited about the potential of this personalised digital approach to such an important global health issue.
What our fund managers say
“We’re really interested in building global businesses in the healthcare space and are super excited about the potential of Quit Genius. When it comes to addiction, far too many people are still dying from deaths that are potentially avoidable if the necessary help is accessible. That’s why this personalised digital approach is so exciting, as it is far more effective at changing behaviours, and it’s easily accessible which will ultimately save lives.”
-Will Gibbs, Octopus Ventures
Key risks to remember
Please remember that the value of an investment in Octopus Titan VCT, and any income from it, can fall as well as rise. Investors may not get back the full amount they invest.
Tax treatment depends on individual circumstances end may change in the future. Tax reliefs depend on the VCT maintaining its qualifying status.
VCT shares could fall or rise in value more than other shares listed on the main market of the London Stock Exchange. They may also be harder to sell.
Investors should only subscribe for shares on the basis of information contained in the prospectus and Key Information Document (KID), available on the Titan VCT product page. Company examples are for illustrative purposes only and should not be considered an investment recommendation.
More companies we’ve backed
We’re here to support you
Got a question?
¹ Statistics on addiction in America, Addiction Centre, September 2021